Hemispherx Biopharma, Inc.
(NYSE MKT:HEB) (the "Company" or "Hemispherx") today announced the outcome of
the meeting of the Arthritis Advisory Committee (the "AAC") of the U.S. Food
and Drug Administration (the "FDA") on the New Drug Application ("NDA") for
Ampligen^® for Chronic Fatigue Syndrome ("CFS").
On the question: "Considering the totality of the data, is there substantial
evidence of efficacy for Ampligen for the treatment of patients with chronic
fatigue syndrome (CFS)?," the AAC voted 9 no, 4 yes and 1 AAC member left the
room and did not vote.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in